<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37567082</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-2026</ISSN><JournalIssue CitedMedium="Internet"><Volume>88</Volume><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Asian journal of psychiatry</Title><ISOAbbreviation>Asian J Psychiatr</ISOAbbreviation></Journal><ArticleTitle>Anxiety due to Long COVID is partially driven by activation of the tryptophan catabolite (TRYCAT) pathway.</ArticleTitle><Pagination><StartPage>103723</StartPage><MedlinePgn>103723</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajp.2023.103723</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1876-2018(23)00279-4</ELocationID><Abstract><AbstractText>This study examines whether activation of the tryptophan catabolite (TRYCAT) pathway is associated with anxiety symptoms due to Long COVID. We selected 90 participants, 60 Long COVID patients and 30 individuals without any symptoms following acute COVID-19 infection. Using cluster analysis and the Hamilton Anxiety Rating scale (HAMA) score, the pure HAMA anxiety score, serum tryptophan (TRP) and kynurenine (KYN), the KYN/TRP ratio (all measured during Long COVID), and oxygen saturation (SpO2) (measured during the acute phase of COVID-19), we were able to classify Long COVID patients into two distinct clusters with an adequate silhouette cohesion and separation index (0.58): cluster 1 (n&#xa0;=&#xa0;61) and cluster 2 (n&#xa0;=&#xa0;29). Cluster 2 patients had lower SpO2 and TRP levels, as well as higher KYN, KYN/TRP ratio, and HAMA scores than cluster 1. Regression analysis revealed that the KYN/TRP ratio explained 14.4&#xa0;% of the variance in the HAMA score (F&#xa0;=&#xa0;14.81, df&#xa0;=&#xa0;1/88, p&#xa0;=&#xa0;0.001). In addition, regression analysis revealed that SpO2 partially explained the variance in serum TRP (r&#xa0;=&#xa0;0.396, p&#xa0;=&#xa0;0.005), KYN/TRP ratio (r&#xa0;=&#xa0;-&#xa0;0.248, p&#xa0;=&#xa0;0.018), and the HAMA score (r&#xa0;=&#xa0;-&#xa0;0.279, p&#xa0;=&#xa0;0.008). The current data imply that decreased SpO2 during the acute phase of COVID-19 infection is predictive of anxiety caused by Long COVID. Our data reveal that around 32&#xa0;% of Long COVID patients have elevated IDO activity in association with elevated anxiety.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al-Hakeim</LastName><ForeName>Hussein Kadhem</ForeName><Initials>HK</Initials><AffiliationInfo><Affiliation>Department of Chemistry, College of Science, University of Kufa, Kufa 54002, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abed</LastName><ForeName>Anwar Khairi</ForeName><Initials>AK</Initials><AffiliationInfo><Affiliation>Department of Chemistry, College of Science, University of Kufa, Kufa 54002, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almulla</LastName><ForeName>Abbas F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouf Moustafa</LastName><ForeName>Shatha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Analysis Department, College of Pharmacy, Hawler Medical University, Erbil, Iraq.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maes</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria; Research Institute, Medical University of Plovdiv, Plovdiv, Bulgaria; Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, the Republic of Korea; Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China; Key Laboratory of Psychosomatic Medicine, Chinese Academy of Medical Sciences, Chengdu 610072, China. Electronic address: dr.michaelmaes@hotmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Asian J Psychiatr</MedlineTA><NlmUniqueID>101517820</NlmUniqueID><ISSNLinking>1876-2018</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8DUH1N11BX</RegistryNumber><NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance></Chemical><Chemical><RegistryNumber>343-65-7</RegistryNumber><NameOfSubstance UI="D007737">Kynurenine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014364" MajorTopicYN="Y">Tryptophan</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007737" MajorTopicYN="N">Kynurenine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Anxiety</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Kynurenine</Keyword><Keyword MajorTopicYN="N">Mood disorders</Keyword><Keyword MajorTopicYN="N">Neuro-immune</Keyword><Keyword MajorTopicYN="N">Tryptophan</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors have no conflicts of interest with any industrial or other association concerning the submitted article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>12</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>11</Day><Hour>18</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37567082</ArticleId><ArticleId IdType="doi">10.1016/j.ajp.2023.103723</ArticleId><ArticleId IdType="pii">S1876-2018(23)00279-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>